Neoadjuvant <sup>177</sup>Lutetium-PSMA-617 Radioligand Therapy for High-Risk Localized Prostate Cancer: Rationale, Early Clinical Evidence, and Future Directions.

Cancers (Basel) · 2025 · PMC12563130 · PMID 41154386

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This outcome, while demonstrating clear biological activity, is highly significant: it strongly suggests that a single cycle of 177 Lu-PSMA-617 monotherapy is insufficient to completely eradicate macroscopic, high-risk localized PCa.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Neoadjuvant &lt;sup&gt;177&lt;/sup&gt;Lutetium-PSMA-617 Radioligand Therapy for High-Risk Localized Prostate Cancer: Rationale, Early Clinical Evidence, and Future Directions.

The sentences

Neoadjuvant <sup>177</sup>Lutetium-PSMA-617 Radioligand Therapy for High-Risk Localized Prostate Cancer: Rationale, Early Clinical Evidence, and Future Directions.